American College of Rheumatology

Pharmacokinetics and immunogenicity were also similar between reference tocilizumab and CT-P47.

Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.

CDC, NIH, and AMA recommend PEMs to be at a 6th-to-8th-grade reading level, while assessed materials were readable at high school or higher levels.

CT-P41 had similar rates of bone mineral density increases and adverse events in data presented at the ACR 2024 Convergence.

Findings from PsABIOnd can help reassure clinicians of similar efficacy between treatment choices.

At the highest dose levels, mean plasma urate levels remained below 6.0 mg/dL for up to 12 weeks.

Stone discussed the phase 3 MITIGATE study, other potential treatment strategies, and top research priorities moving forward for IgG4.

Patients in the anifrolumab arm also had lower rates of damage accrual.

Conaghan discussed findings from a phase 2 trial at the ACR 2024 Convergence.

The findings are especially important as differences in disease characteristics and outcomes between male and female patients become more clear.

At ACR, HCPLive spoke with Erin Treemarcki on a survey that showed many rheumatologists do not use established enthesitis scoring measures for children.

Hypovitaminosis D was more prevalent in patients with lupus nephritis compared to patients with systemic lupus erythematosus without kidney disease.

Clinically meaningful increases in patient-reported outcomes were identified after 3 doses of SEL-212 and strengthened after 3 additional doses.

At ACR, HCPLive spoke with Ashima Makol, MD, about factors linked to a worse health-related quality of life in patients with early systemic sclerosis.

Emapalumab may improve outcomes in patients with MAS whose disease didn’t respond to steroid therapy and mitigate the need for more toxic therapies.

The Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) was linked to fewer gout-related hospital admissions.

Arnold discussed his research in analyzing and improving current classifications of ANA-RMDs and how it could help improve research in the field.

Tesser discussed the background of the phase 3 RESET-RA trial and efficacy findings.

Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.

Noaiseh discussed data from the DAHLIAS study linking, for the first time, clinical responses, with autoantibody levels.

Over half of patients treated with LEVI-04 had at least a 50% reduction in pain and over 25% had at least a 75% reduction.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.

However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.

Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.

Just discussed data from 2 studies demonstrating efficacy of AI assessment compared to clinician assessment.

Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.

Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.